What is Homozygous Familial Hypercholesterolemia?
Homozygous Familial Hypercholesterolaemia (HoFH) is a rare and life-threatening disease originally characterized clinically by plasma cholesterol levels >13 mmol/L (>500 mg/dL), extensive xanthomas, and marked premature and progressive atherosclerotic cardiovascular disease (ACVD). It is a more serious form of Familial Hypercholesterolemia (FH), which is an autosomal dominant genetic disorder.
How has Homozygous Familial Hypercholesterolemia affected population?
Homozygous Familial Hypercholesterolemia Epidemiology
Key findings of Homozygous Familial Hypercholesterolemia Market
According to DelveInsight, the market size of HoFH in the 7MM is estimated to be USD 159.5 Million in 2020.
To know more, request sample pages @Homozygous Familial Hypercholesterolemia Market Landscape
Scope of the Report
How many key players are involved in developing Homozygous Familial Hypercholesterolemia therapies?
The dynamics of Homozygous Familial Hypercholesterolemia market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the disease, incremental healthcare spending across the world and the expected launch of emerging therapies during the forecast period. Key players such as Regeneron Pharmaceuticals, Sanofi, LIB Therapeutics, Arrowhead Pharmaceuticals, Novartis, and others are involved in developing treatments for HoFH.
Request sample pages for more information on Homozygous Familial Hypercholesterolemia Market Size
Media ContactCompany Name: DelveInsightContact Person: Priya MauryaEmail: Send EmailPhone: +919650213330City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/